Merck Initiates Three Phase 2b Trials Evaluating Safety And Efficacy Of Tulisokibart In Patients With Three Immune-Mediated Inflammatory Diseases

Author: Benzinga Newsdesk | October 06, 2025 06:49am

Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn's disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and rheumatoid arthritis

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases:

• MK-7240-12 (NCT06956235) studying patients with moderate to severe hidradenitis suppurativa (HS)
• MK-7240-013 (NCT07133633) studying patients with radiographic axial spondyloarthritis (r-axSpA; also known as ankylosing spondylitis)
• MK-7240-014 (NCT07176390) studying patients with rheumatoid arthritis (RA)

Global recruitment of these trials has begun, targeting enrollment of more than 640 patients across the three studies.

Posted In: MRK